F. Hoffmann-La Roche Ltd. is Swiss multinational company established in 1896 by Fritz Hoffmann-La Roche, which specializes in two mainstream profiles: pharmaceuticals and healthcare diagnostics.
![[Image: roche.png]](http://s21.postimg.org/unp3lt81v/roche.png)
The company is headquartered in Basel and the company has many hot centers around the world - including:
USA & CANADA: Nutley, NJ; Pleasanton, CA; Branchburg, NJ; Indianapolis, Indiana; Florence, South Carolina; and Ponce, Puerto Rico; Mississauga and Laval in Canada.
SOUTH AMERICA: São Paulo, Brazil;
EUROPE: Welwyn Garden City and Burgess Hill in the UK; Clarecastle in Ireland; Mannheim and Penzberg in Germany; Segrate, Milan in Italy;
ASIA Shanghai in China; Mumbai & Hyderabad in India; Karachi, Islamabad and Lahore in Pakistan.
Roche also holds the American biotechnology company Genentech, which is a wholly owned affiliate, the Japanese biotechnology company Chugai Pharmaceuticals and the Tucson, Arizona based Ventana
The company has a legacy of invention, its has credits for presenting The World of medicine, first anti-depressant Iproniazid and one of the most powerful statin Xenical
In this forum we will discuss about the latest updates of the company and the vacancies.
With its huge steps for mergers and acquisitions growth of Roche looks unstoppable. This July (07-02-2013) company has acquired a Boston based company Constitution Medical Inc. This will make the hematology section of Roche quite robust. A total of USD 2.0 billion of global market is estimated for hematology testing post this well thought move.
Perjeta, in combination with Herceptin and chemotherapy, was approved by the FDA in 2012 for HER2-positive metastatic breast cancer. Now it is proposed to be used as a neoadjuvant therapy where it will be used before surgery of HER-2 positive breast cancer. But the treatment is restricted to patients where cancer has not spread beyond the breasts or the lymph nodes. It was studied that treatment with Perjeta, Herceptin and docetaxel chemotherapy significantly improved the rate of pCR by 58 percent compared to Herceptin and docetaxel alone (45.8 percent vs. 29.0 percent, p=0.014).
FDA has granted a priority review for of the application and the results can be expected by October 31, 2013.
Are you a biotech/pharma graduate? And want to have a future in management division of a pharma company? Then definitely Be Roche program is for you. It specializes the student in eleven divisions-
- Human Resources
- Finance and Administration
- Marketing
- Medical Marketing
- Corporate Communications
- Sales
- Business Initiatives
- Health Economics
- Regulatory Affairs
- Medical Services
- Analytics
If you have talent to show up in multidimensional aspect this is the pathlight to a successful career.
Have a look into reviews of past graduates, click here.
Vacancies are listed as per countries, all enthusiasts should give a look at the career site for a bright shining future with one of the most invention driven company.
![[Image: roche_Copy.jpg]](http://s12.postimg.org/7viwqow15/roche_Copy.jpg)
Do follow the post for regular updates!
The company is headquartered in Basel and the company has many hot centers around the world - including:
USA & CANADA: Nutley, NJ; Pleasanton, CA; Branchburg, NJ; Indianapolis, Indiana; Florence, South Carolina; and Ponce, Puerto Rico; Mississauga and Laval in Canada.
SOUTH AMERICA: São Paulo, Brazil;
EUROPE: Welwyn Garden City and Burgess Hill in the UK; Clarecastle in Ireland; Mannheim and Penzberg in Germany; Segrate, Milan in Italy;
ASIA Shanghai in China; Mumbai & Hyderabad in India; Karachi, Islamabad and Lahore in Pakistan.
Roche also holds the American biotechnology company Genentech, which is a wholly owned affiliate, the Japanese biotechnology company Chugai Pharmaceuticals and the Tucson, Arizona based Ventana
The company has a legacy of invention, its has credits for presenting The World of medicine, first anti-depressant Iproniazid and one of the most powerful statin Xenical
In this forum we will discuss about the latest updates of the company and the vacancies.
With its huge steps for mergers and acquisitions growth of Roche looks unstoppable. This July (07-02-2013) company has acquired a Boston based company Constitution Medical Inc. This will make the hematology section of Roche quite robust. A total of USD 2.0 billion of global market is estimated for hematology testing post this well thought move.
Perjeta, in combination with Herceptin and chemotherapy, was approved by the FDA in 2012 for HER2-positive metastatic breast cancer. Now it is proposed to be used as a neoadjuvant therapy where it will be used before surgery of HER-2 positive breast cancer. But the treatment is restricted to patients where cancer has not spread beyond the breasts or the lymph nodes. It was studied that treatment with Perjeta, Herceptin and docetaxel chemotherapy significantly improved the rate of pCR by 58 percent compared to Herceptin and docetaxel alone (45.8 percent vs. 29.0 percent, p=0.014).
FDA has granted a priority review for of the application and the results can be expected by October 31, 2013.
Are you a biotech/pharma graduate? And want to have a future in management division of a pharma company? Then definitely Be Roche program is for you. It specializes the student in eleven divisions-
- Human Resources
- Finance and Administration
- Marketing
- Medical Marketing
- Corporate Communications
- Sales
- Business Initiatives
- Health Economics
- Regulatory Affairs
- Medical Services
- Analytics
If you have talent to show up in multidimensional aspect this is the pathlight to a successful career.
Have a look into reviews of past graduates, click here.
Vacancies are listed as per countries, all enthusiasts should give a look at the career site for a bright shining future with one of the most invention driven company.
Do follow the post for regular updates!
![[+]](https://www.biotechnologyforums.com/images/netpen-pro/collapse_collapsed.png)